Biofrontera Inc. (BFRI)
(Real Time Quote from BATS)
$1.68 USD
+0.09 (5.66%)
Updated Apr 29, 2024 01:20 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
BFRI 1.68 +0.09(5.66%)
Will BFRI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BFRI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BFRI
Biofrontera Inc. (BFRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's What You Should Know
BFRI: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Biofrontera Inc. (BFRI) Rating Upgrade to Buy
Biofrontera Inc. (BFRI) Reports Q2 Loss, Lags Revenue Estimates
Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Lags Revenue Estimates
Other News for BFRI
12 Health Care Stocks Moving In Monday's After-Market Session
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million
Analysts’ Top Healthcare Picks: Biofrontera (BFRI), Alpine Immune Sciences (ALPN)
Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript